title: Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping.
abstract: Immunophenotypic characterization of B-cell chronic lymphoproliferative disorders (B-CLPD) is becoming increasingly complex due to usage of progressively larger panels of reagents and a high number of World Health Organization (WHO) entities. Typically, data analysis is performed separately for each stained aliquot of a sample; subsequently, an expert interprets the overall immunophenotypic profile (IP) of neoplastic B-cells and assigns it to specific diagnostic categories. We constructed a principal component analysis (PCA)-based tool to guide immunophenotypic classification of B-CLPD. Three reference groups of immunophenotypic data files-B-cell chronic lymphocytic leukemias (B-CLL; n = 10), mantle cell (MCL; n = 10) and follicular lymphomas (FL; n = 10)--were built. Subsequently, each of the 175 cases studied was evaluated and assigned to either one of the three reference groups or to none of them (other B-CLPD). Most cases (89%) were correctly assigned to their corresponding WHO diagnostic group with overall positive and negative predictive values of 89 and 96%, respectively. The efficiency of the PCA-based approach was particularly high among typical B-CLL, MCL and FL vs other B-CLPD cases. In summary, PCA-guided immunophenotypic classification of B-CLPD is a promising tool for standardized interpretation of tumor IP, their classification into well-defined entities and comprehensive evaluation of antibody panels.
authors.affiliation: Pediatrics Institute Martagão Gesteira-IPPMG, Federal University of Rio de Janeiro-UFRJ, Rio de Janeiro, Brazil.
authors.forename: E S
authors.initials: ES
authors.lastname: Costa
authors.forename: C E
authors.initials: CE
authors.lastname: Pedreira
authors.forename: S
authors.initials: S
authors.lastname: Barrena
authors.forename: Q
authors.initials: Q
authors.lastname: Lecrevisse
authors.forename: J
authors.initials: J
authors.lastname: Flores
authors.forename: S
authors.initials: S
authors.lastname: Quijano
authors.forename: J
authors.initials: J
authors.lastname: Almeida
authors.forename: M
authors.initials: M
authors.lastname: del Carmen García-Macias
authors.forename: S
authors.initials: S
authors.lastname: Bottcher
authors.forename: J J M
authors.initials: JJ
authors.lastname: Van Dongen
authors.forename: A
authors.initials: A
authors.lastname: Orfao
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000276:immunology; D001331:Automation; D001402:B-Lymphocytes / Q000276:immunology* / Q000473:pathology; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D016130:Immunophenotyping / Q000379:methods; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology* / Q000473:pathology; D008223:Lymphoma / Q000276:immunology / Q000473:pathology; D008224:Lymphoma, Follicular / Q000276:immunology / Q000473:pathology; D020522:Lymphoma, Mantle-Cell / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests
chemical_list: D015703:Antigens, CD; D007070:Immunoglobulin A